These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 12516939)

  • 1. Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness.
    Simon MW; Fish DN; Deeter RG
    Drugs R D; 2002; 3(6):365-73. PubMed ID: 12516939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections.
    Perry CM; Faulds D
    Drugs; 1996 Nov; 52(5):754-72. PubMed ID: 9118821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.
    Wang LH; Schultz M; Weller S; Smiley ML; Blum MR
    Antimicrob Agents Chemother; 1996 Jan; 40(1):80-5. PubMed ID: 8787884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.
    Weller S; Blum MR; Doucette M; Burnette T; Cederberg DM; de Miranda P; Smiley ML
    Clin Pharmacol Ther; 1993 Dec; 54(6):595-605. PubMed ID: 8275615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valaciclovir: a review of its use in the management of herpes zoster.
    Ormrod D; Goa K
    Drugs; 2000 Jun; 59(6):1317-40. PubMed ID: 10882165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects.
    Gimenez F; Foeillet E; Bourdon O; Weller S; Garret C; Bidault R; Singlas E
    Clin Pharmacokinet; 2004; 43(10):685-92. PubMed ID: 15244498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group.
    Bodsworth NJ; Crooks RJ; Borelli S; Vejlsgaard G; Paavonen J; Worm AM; Uexkull N; Esmann J; Strand A; Ingamells AJ; Gibb A
    Genitourin Med; 1997 Apr; 73(2):110-6. PubMed ID: 9215092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease.
    Jacobson MA; Gallant J; Wang LH; Coakley D; Weller S; Gary D; Squires L; Smiley ML; Blum MR; Feinberg J
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1534-40. PubMed ID: 7979285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age.
    Kimberlin DW; Jacobs RF; Weller S; van der Walt JS; Heitman CK; Man CY; Bradley JS
    Clin Infect Dis; 2010 Jan; 50(2):221-8. PubMed ID: 20014952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients.
    Stathoulopoulou F; Dhillon S; Thodis H; Stathakis C; Vargemezis V
    Nephron; 2002 May; 91(1):164-6. PubMed ID: 12021536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new paediatric formulation of valaciclovir: development and bioequivalence assessment.
    Bastiaans DE; Bartels-Wilmer CM; Colbers AP; Heijens CA; Velthoven-Graafland K; Smeets OS; Vink N; Harbers VE; Warris A; Burger DM
    Arch Dis Child; 2016 Oct; 101(10):971-2. PubMed ID: 27162003
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients.
    Höglund M; Ljungman P; Weller S
    J Antimicrob Chemother; 2001 Jun; 47(6):855-61. PubMed ID: 11389118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.
    Johnston C; Saracino M; Kuntz S; Magaret A; Selke S; Huang ML; Schiffer JT; Koelle DM; Corey L; Wald A
    Lancet; 2012 Feb; 379(9816):641-7. PubMed ID: 22225814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment.
    Helldén A; Lycke J; Vander T; Svensson JO; Odar-Cederlöf I; Ståhle L
    J Antimicrob Chemother; 2006 May; 57(5):945-9. PubMed ID: 16540518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valaciclovir (BW256U87): the L-valyl ester of acyclovir.
    Jacobson MA
    J Med Virol; 1993; Suppl 1():150-3. PubMed ID: 8245883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.
    Ormrod D; Scott LJ; Perry CM
    Drugs; 2000 Apr; 59(4):839-63. PubMed ID: 10804039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.
    Soul-Lawton J; Seaber E; On N; Wootton R; Rolan P; Posner J
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2759-64. PubMed ID: 8593015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy.
    Steingrimsdottir H; Gruber A; Palm C; Grimfors G; Kalin M; Eksborg S
    Antimicrob Agents Chemother; 2000 Jan; 44(1):207-9. PubMed ID: 10602752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus.
    Colin J; Prisant O; Cochener B; Lescale O; Rolland B; Hoang-Xuan T
    Ophthalmology; 2000 Aug; 107(8):1507-11. PubMed ID: 10919899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.